Factors affecting the persistence of drug-induced reprogramming of the cancer methylome

Abstract

Aberrant DNA methylation is a critical feature of cancer. Epigenetic therapy seeks to reverse these changes to restore normal gene expression. DNA demethylating agents, including 5-aza-2 0 -deoxycytidine (DAC), are currently used to treat certain leukemias, and can sensitize solid tumors to chemotherapy and immunotherapy. However, it has been difficult to pin the clinical efficacy of these agents to specific demethylation events, and the factors that contribute to the durability of response remain largely unknown. Here we examined the genome-wide kinetics of DAC-induced DNA demethylation and subsequent remethylation after drug withdrawal in breast cancer cells. We find that CpGs differ in both their susceptibility to demethylation and propensity for remethylation after drug removal. DAC-induced demethylation was most apparent at CpGs with higher initial methylation levels and further from CpG islands. Once demethylated, such sites exhibited varied remethylation potentials. The most rapidly remethylating CpGs regained >75% of their starting methylation within a month of drug withdrawal. These sites had higher pretreatment methylation levels, were enriched in gene bodies, marked by H3K36me3, and tended to be methylated in normal breast cells. In contrast, a more resistant class of CpG sites failed to regain even 20% of their initial methylation after 3 months. These sites had lower pretreatment methylation levels, were within or near CpG islands, marked by H3K79me2 or H3K4me2/3, and were overrepresented in sites that become aberrantly hypermethylated in breast cancers. Thus, whereas DAC-induced demethylation affects both endogenous and aberrantly methylated sites, tumorspecific hypermethylation is more slowly regained, even as normal methylation promptly recovers. Taken together, these data suggest that the durability of DAC response is linked to its selective ability to stably reset at least a portion of the cancer methylome.

A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes

“…Genome-wide kinetics of DAC-induced DNA demethylation and subsequent remethylation after drug withdrawal in breast cancer cells showed that CpGs differ in both their susceptibility to demethylation and propensity for remethylation after drug removal (44). This is also plausible since EZH2 recruits DNMTs directly and indirectly through PRC2 (13, 15).…”

DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase

“…DNA hypermethylation in cancer cells may be reversed by DNA methyltransferase inhibitors, such 5-aza-2 0 -deoxycytidine , that cause passive genome-wide DNA demethylation and have antitumoral properties in vivo [8]. However, demethylation is followed by re-methylation after drug withdrawal [9], which limits their usefulness for functional studies.…”